JP2020531525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531525A5 JP2020531525A5 JP2020511319A JP2020511319A JP2020531525A5 JP 2020531525 A5 JP2020531525 A5 JP 2020531525A5 JP 2020511319 A JP2020511319 A JP 2020511319A JP 2020511319 A JP2020511319 A JP 2020511319A JP 2020531525 A5 JP2020531525 A5 JP 2020531525A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023027219A JP2023062184A (ja) | 2017-08-23 | 2023-02-24 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US62/549,201 | 2017-08-23 | ||
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US62/558,509 | 2017-09-14 | ||
| US62/558,514 | 2017-09-14 | ||
| US62/558,510 | 2017-09-14 | ||
| US62/558,511 | 2017-09-14 | ||
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US62/566,828 | 2017-10-02 | ||
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US62/581,357 | 2017-11-03 | ||
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| US62/608,384 | 2017-12-20 | ||
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023027219A Division JP2023062184A (ja) | 2017-08-23 | 2023-02-24 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531525A JP2020531525A (ja) | 2020-11-05 |
| JP2020531525A5 true JP2020531525A5 (enExample) | 2021-09-30 |
Family
ID=65439284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511319A Ceased JP2020531525A (ja) | 2017-08-23 | 2018-08-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質 |
| JP2023027219A Pending JP2023062184A (ja) | 2017-08-23 | 2023-02-24 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023027219A Pending JP2023062184A (ja) | 2017-08-23 | 2023-02-24 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (enExample) |
| EP (1) | EP3672993A4 (enExample) |
| JP (2) | JP2020531525A (enExample) |
| KR (1) | KR20200038530A (enExample) |
| CN (1) | CN111315778A (enExample) |
| AU (1) | AU2018322178A1 (enExample) |
| BR (1) | BR112020003654A2 (enExample) |
| CA (1) | CA3072919A1 (enExample) |
| IL (2) | IL311488A (enExample) |
| MX (1) | MX2020002036A (enExample) |
| RU (1) | RU2020111554A (enExample) |
| SG (1) | SG11201913968VA (enExample) |
| WO (1) | WO2019040727A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| WO2021150598A1 (en) * | 2020-01-20 | 2021-07-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| TWI825544B (zh) | 2020-12-31 | 2023-12-11 | 大陸商信達生物製藥（蘇州）有限公司 | 含異二聚體抗體Ｆｃ的蛋白以及其製備方法 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
| CN118812708B (zh) * | 2024-06-28 | 2025-04-04 | 北京普利米特生物科技有限公司 | 抗il-33抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266014A2 (en) * | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| RU2744046C2 (ru) * | 2014-03-05 | 2021-03-02 | Отолус Лимитед | ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的抗原結合タンパク質 |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20190031785A1 (en) * | 2016-01-13 | 2019-01-31 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
-
2018
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en not_active Ceased
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en not_active Abandoned
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en not_active Withdrawn
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Ceased
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt not_active IP Right Cessation
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja not_active Ceased
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| CN107405397B (zh) | 抗tim-3抗体 | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP2024036342A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| ES2358427T3 (es) | Elementos de unión a cd-3 desinmunizados multiespecíficos. | |
| CN101420978B (zh) | 通过三官能双特异性抗体破坏表达低至中等水平的肿瘤相关靶抗原的肿瘤细胞 | |
| JP2021098732A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| IL273424B1 (en) | Novel bispecific cd3/cd19 polypeptide complexes | |
| JP2020522473A5 (enExample) | ||
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2021519072A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2017505121A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2020529410A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| TW201920272A (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| US20180371089A1 (en) | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen |